The specter of generic rivalry has long loomed around copyright’s blockbuster drug, Viagra, raising questions about the future of similar drug ventures. While early periods saw impressive profits, the patent lapse has created the way for discounted substitutes, potentially reducing earnings and posing a genuine danger for investors pursuing secur